Dragonfly Therapeutics Announces AbbVie Opt-In of TriNKET™ Immunotherapy Drug Candidate
- Tuesday, January 12, 2021, 7:01
- Finance
- Add a comment
Dragonfly to receive payment for the first Opt-In from AbbVie as part of a multi-target collaboration launched just over 1 year ago. WALTHAM, Mass., Jan. 12, 2021 /PRNewswire/ — Dragonfly Therapeutics (“Dragonfly”), a biotechnology company developing novel immunotherapies that harness…
About the Author
adminasapcorp has written 41562 stories on this site.